

 
                    "Advancing obesity and obesity-related trials with patients at the center of development.
LEARN MORE 
                Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview 
                Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW 
                Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW 
                Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW 
                When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS 
                By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE 
                Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE 
                Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE 
                The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE 
                The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE 
                IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE 
                Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE 
                    "At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESDermatologic conditions, including hair, skin and nail disorders, are estimated to impact one-third of the global population. Drug developers are taking note; the global commercial dermatology market is estimated to reach $33.7 billion by 2022, rising at a 7.73 percent CAGR from 2015 to 2022.1 Historically, dermatology treatment options could largely be classified as topical, phototherapy, or conventional drugs delivered systemically. More recently, research has led to exploration of another treatment option: biologics.
The emergence of biologic therapies for dermatologic conditions created a paradigm shift for patients, physicians and sponsors. Typically offered as a secondor third-line therapy, biologics offer treatment options for patients often with the most severe or debilitating presentations of dermatologic conditions. These options are increasing; a May 2016 report from GBI estimates 37 percent of the approximately 800 dermatology products in development are biologic agents.
This white paper will explore the evolution of biologics within the dermatology landscape, with an emphasis on clinical trial considerations and best practices for sponsors developing biologic agents.
Biologics, derived from living organisms, have been in use for decades (e.g., insulin or vaccines derived from eggs). Today’s biologics – those developed in the past 15 years – are protein-based drugs created from genetically modified cells. Biologic agents can target more specific areas of the immune system than the “small molecule” systemic drugs that tend to impact the body’s overall immunity.